JP2017222705A5 - - Google Patents

Download PDF

Info

Publication number
JP2017222705A5
JP2017222705A5 JP2017149548A JP2017149548A JP2017222705A5 JP 2017222705 A5 JP2017222705 A5 JP 2017222705A5 JP 2017149548 A JP2017149548 A JP 2017149548A JP 2017149548 A JP2017149548 A JP 2017149548A JP 2017222705 A5 JP2017222705 A5 JP 2017222705A5
Authority
JP
Japan
Prior art keywords
dosage form
oral dosage
solid oral
dimethyl fumarate
form according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017149548A
Other languages
English (en)
Japanese (ja)
Other versions
JP6430598B2 (ja
JP2017222705A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017222705A publication Critical patent/JP2017222705A/ja
Publication of JP2017222705A5 publication Critical patent/JP2017222705A5/ja
Application granted granted Critical
Publication of JP6430598B2 publication Critical patent/JP6430598B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017149548A 2012-02-07 2017-08-02 フマル酸ジメチルを含有する医薬組成物 Expired - Fee Related JP6430598B2 (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261596202P 2012-02-07 2012-02-07
US61/596,202 2012-02-07
US201261625621P 2012-04-17 2012-04-17
US61/625,621 2012-04-17
US201261723048P 2012-11-06 2012-11-06
US61/723,048 2012-11-06

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014555852A Division JP6189333B2 (ja) 2012-02-07 2013-02-06 フマル酸ジメチルを含有する医薬組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018204599A Division JP2019059732A (ja) 2012-02-07 2018-10-31 フマル酸ジメチルを含有する医薬組成物

Publications (3)

Publication Number Publication Date
JP2017222705A JP2017222705A (ja) 2017-12-21
JP2017222705A5 true JP2017222705A5 (enExample) 2018-03-22
JP6430598B2 JP6430598B2 (ja) 2018-11-28

Family

ID=48947963

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2014555852A Expired - Fee Related JP6189333B2 (ja) 2012-02-07 2013-02-06 フマル酸ジメチルを含有する医薬組成物
JP2017149548A Expired - Fee Related JP6430598B2 (ja) 2012-02-07 2017-08-02 フマル酸ジメチルを含有する医薬組成物
JP2018204599A Pending JP2019059732A (ja) 2012-02-07 2018-10-31 フマル酸ジメチルを含有する医薬組成物
JP2021184462A Pending JP2022024048A (ja) 2012-02-07 2021-11-12 フマル酸ジメチルを含有する医薬組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2014555852A Expired - Fee Related JP6189333B2 (ja) 2012-02-07 2013-02-06 フマル酸ジメチルを含有する医薬組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018204599A Pending JP2019059732A (ja) 2012-02-07 2018-10-31 フマル酸ジメチルを含有する医薬組成物
JP2021184462A Pending JP2022024048A (ja) 2012-02-07 2021-11-12 フマル酸ジメチルを含有する医薬組成物

Country Status (24)

Country Link
US (7) US20130216615A1 (enExample)
EP (1) EP2811994A4 (enExample)
JP (4) JP6189333B2 (enExample)
KR (1) KR102105217B1 (enExample)
CN (5) CN114146081A (enExample)
AR (1) AR089931A1 (enExample)
AU (6) AU2013203445C1 (enExample)
BR (1) BR112014019462B1 (enExample)
CA (1) CA2862885C (enExample)
CL (1) CL2014002077A1 (enExample)
CO (1) CO7141407A2 (enExample)
EA (1) EA038152B1 (enExample)
EC (1) ECSP14014870A (enExample)
HK (1) HK1202261A1 (enExample)
IL (2) IL233833B (enExample)
MX (2) MX393165B (enExample)
NI (1) NI201400086A (enExample)
NZ (1) NZ627980A (enExample)
PE (1) PE20150092A1 (enExample)
PH (1) PH12014501750A1 (enExample)
SG (1) SG11201404705YA (enExample)
TW (4) TWI676475B (enExample)
WO (1) WO2013119677A1 (enExample)
ZA (1) ZA201405511B (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE380027T1 (de) 2003-09-09 2007-12-15 Fumapharm Ag Verwendung von fumarsäure-derivaten zur behandlung von herzinsuffizienz und asthma
DE14172396T1 (de) 2004-10-08 2015-01-08 Forward Pharma A/S Gesteuerte Freisetzung von pharmazeutischen Zusammensetzungen mit Fumarinsäureester
WO2008096271A2 (en) * 2007-02-08 2008-08-14 Ralf Gold Neuroprotection in demyelinating diseases
RU2554347C2 (ru) 2008-08-19 2015-06-27 Ксенопорт, Инк. Пролекарства метилгидрофумарата, фармацевтические композиции с ними и способы применения
MX355421B (es) 2011-06-08 2018-04-18 Biogen Ma Inc Proceso para preparar fumarato de dimetilo cristalino y de alta pureza.
AU2013203445C1 (en) * 2012-02-07 2017-04-20 Biogen Ma Inc. Pharmaceutical compositions containing dimethyl fumarate
AU2013305684B2 (en) 2012-08-22 2016-11-24 Xenoport, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
EP2887934A1 (en) 2012-08-22 2015-07-01 XenoPort, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
EP3566701A1 (en) 2012-12-21 2019-11-13 Biogen MA Inc. Deuterium substituted fumarate derivatives
UA116648C2 (uk) 2013-03-14 2018-04-25 Алкермес Фарма Айерленд Лімітед Фумарати як проліки та їх застосування при лікуванні різних захворювань
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
WO2014143146A1 (en) * 2013-03-15 2014-09-18 Xenoport, Inc. Methods of administering monomethyl fumarate
WO2014160633A1 (en) 2013-03-24 2014-10-02 Xenoport, Inc. Pharmaceutical compositions of dimethyl fumarate
US9302977B2 (en) 2013-06-07 2016-04-05 Xenoport, Inc. Method of making monomethyl fumarate
WO2014205392A1 (en) 2013-06-21 2014-12-24 Xenoport, Inc. Cocrystals of dimethyl fumarate
WO2015035184A1 (en) 2013-09-06 2015-03-12 Xenoport, Inc. Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use
DK3079666T3 (da) * 2013-12-12 2021-03-22 Almirall Sa Farmaceutiske sammensætninger omfattende dimethylfumarat
US10172794B2 (en) 2013-12-13 2019-01-08 Biogen Ma Inc. Controlled release dosage form for once daily administration of dimethyl fumarate
US9604922B2 (en) 2014-02-24 2017-03-28 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
EP3501510B1 (en) 2014-02-28 2020-07-01 Banner Life Sciences LLC Controlled release enteric soft capsules of fumarate esters
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
EP3650042A1 (en) 2014-03-14 2020-05-13 Biogen MA Inc. Dimethyl fumarate and vaccination regimens
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
AU2015328676B2 (en) * 2014-10-08 2017-07-20 Banner Life Sciences Llc Controlled release enteric soft capsules of fumarate esters
EP3212626B1 (en) * 2014-10-27 2018-11-07 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
MA40985A (fr) 2014-11-17 2017-09-26 Biogen Ma Inc Méthodes de traitement de la sclérose en plaques
MA40990A (fr) * 2014-11-19 2017-09-26 Biogen Ma Inc Formulations de matrice pharmaceutique comprenant du fumarate de diméthyle
MA40982A (fr) * 2014-11-19 2017-09-26 Biogen Ma Inc Formulation de bille pharmaceutique comprenant du fumarate de diméthyle
CN104490849A (zh) * 2014-11-24 2015-04-08 广东东阳光药业有限公司 一种高密度的富马酸二甲酯肠溶颗粒及其制备方法
MA41139A (fr) 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
AU2015359346B2 (en) 2014-12-11 2020-05-07 Laboratoires Juvise Pharmaceuticals Dosing regimen for a selective S1P1 receptor agonist
HK1253050A1 (zh) * 2015-02-02 2019-06-06 英仕柏集团有限责任公司 稳定的富马酸二烷基酯组合物
JP2018503651A (ja) * 2015-02-08 2018-02-08 アルカーメス ファーマ アイルランド リミテッド フマル酸モノメチルプロドラッグ組成物
AU2016231883B2 (en) * 2015-03-17 2019-03-07 Hetero Labs Limited Pharmaceutical compositions of dimethyl fumarate
MA41785A (fr) 2015-03-20 2018-01-23 Biogen Ma Inc Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques
CA2987895A1 (en) 2015-06-01 2016-12-08 Sun Pharmaceutical Industries Ltd. Pharmaceutical compositions of dimethyl fumarate
JP2018517735A (ja) * 2015-06-17 2018-07-05 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． フマル酸ジメチル粒子及びそれらの医薬組成物
WO2017056107A1 (en) * 2015-09-28 2017-04-06 Natco Pharma Ltd Pharmaceutical compositions of dimethyl fumarate
WO2017072699A1 (en) * 2015-10-28 2017-05-04 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of dimethyl fumarate
CA3007483C (en) 2015-12-31 2021-12-07 Zaklady Farmaceutyczne Polpharma S.A. Process for preparation of an enteric coated granulate comprising dimethyl fumarate
EP3407873B1 (en) * 2016-01-28 2024-08-21 Zaklady Farmaceutyczne Polpharma S.A. Process for preparation of a granulate comprising dimethyl fumarate
KR20180108814A (ko) * 2016-02-11 2018-10-04 바이오젠 엠에이 인코포레이티드 다이메틸 퓨마레이트를 포함하는 약제학적 비드 제형
WO2017145036A1 (en) * 2016-02-25 2017-08-31 Aurobindo Pharma Ltd Pharmaceutical compositions comprising dimethyl fumarate
TR201616998A1 (en) 2016-11-23 2018-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi DELAYED RELEASE DOSING FORMS WITH DIMETHYL FUMARATE
CN110475547A (zh) 2017-03-17 2019-11-19 维塔利斯公司 治疗多发性硬化症的组合物和方法
CN110636838A (zh) 2017-06-23 2019-12-31 阿尔米雷尔有限公司 包含反丁烯二酸二甲酯的药物组合物
US20210251910A1 (en) * 2018-09-10 2021-08-19 Vitalis Llc Fumaric acid compositions with increased bioavailability and reduced side effects
US11446055B1 (en) 2018-10-18 2022-09-20 Lumoptik, Inc. Light assisted needle placement system and method
TR201818293A2 (tr) 2018-11-30 2020-06-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Di̇meti̇l fumarat i̇çeren geci̇kmeli̇ salim sağlayan kapsül
WO2021142062A1 (en) * 2020-01-10 2021-07-15 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability
EP4117785A4 (en) 2020-03-13 2024-04-17 Marc J. Simard METHODS OF TREATMENT OF MULTIPLE SCLEROSIS
CA3182369A1 (en) 2020-05-06 2021-07-22 Imcyse Sa Combination treatment for fumarate-related diseases
AU2022285951A1 (en) * 2021-06-04 2024-01-04 Zim Laboratories Limited Delayed release compositions of dimethyl fumarate
US20250282721A9 (en) 2021-12-23 2025-09-11 Gencaps Sàrl Drug delivery system comprising monomethyl fumarate
CN115590831A (zh) * 2022-10-26 2023-01-13 力品药业（厦门）股份有限公司（Cn） 一种富马酸二甲酯缓释微片及其制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1153927A (en) 1966-08-25 1969-06-04 Wilhelm Hoerrmann Medicinal Composition Suitable For Treating Diseases Of The Retina
US5424332A (en) 1987-10-19 1995-06-13 Speiser; Peter P. Pharmaceutical composition and process for the production thereof
US4959389A (en) * 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
US5484610A (en) 1991-01-02 1996-01-16 Macromed, Inc. pH and temperature sensitive terpolymers for oral drug delivery
DE19721099C2 (de) 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten
FI109088B (fi) * 1997-09-19 2002-05-31 Leiras Oy Tabletti ja menetelmä sen valmistamiseksi
DE19814358C2 (de) 1998-03-31 2002-01-17 Fumapharm Ag Muri Verwendung von Alkylhydrogenfumaraten zur Behandlung von Psoriasis, psoriatischer Arthritis, Neurodermitis und Enteritis regionalis Crohn
DE19839566C2 (de) * 1998-08-31 2002-01-17 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten in der Transplantationsmedizin
DE19848260C2 (de) * 1998-10-20 2002-01-17 Fumapharm Ag Muri Fumarsäure-Mikrotabletten
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
US6537584B1 (en) 1999-11-12 2003-03-25 Macromed, Inc. Polymer blends that swell in an acidic environment and deswell in a basic environment
DE10000577A1 (de) * 2000-01-10 2001-07-26 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
US6399101B1 (en) 2000-03-30 2002-06-04 Mova Pharmaceutical Corp. Stable thyroid hormone preparations and method of making same
BR0210867A (pt) 2001-07-06 2004-06-29 Lifecycle Pharma As Processo para a preparação de um material particulado, métodos para aglomeração controlada de um material sólido finamente disperso, para melhorar a biodisponibilidade de uma substância terapêutica e/ou profilaticamente ativa, e para melhorar a vida em prateleira de uma composição farmacêutica, material articulado, composição farmacêutica, uso de um veìculo, material particulado farmacêutico, e, uso de aluminossilicato de magnésio e/ou de aluminometassilicato de magnésio
KR100540035B1 (ko) * 2002-02-01 2005-12-29 주식회사 태평양 다단계 경구 약물 방출 제어 시스템
DE10214031A1 (de) 2002-03-27 2004-02-19 Pharmatech Gmbh Verfahren zur Herstellung und Anwendung von Mikro- und Nanoteilchen durch aufbauende Mikronisation
BRPI0408323A (pt) * 2003-03-14 2006-03-07 Nirmal Mulye processo para a preparação de compimidos de liberação prolongada
ATE380027T1 (de) * 2003-09-09 2007-12-15 Fumapharm Ag Verwendung von fumarsäure-derivaten zur behandlung von herzinsuffizienz und asthma
DE10360869A1 (de) * 2003-09-09 2005-04-07 Fumapharm Ag Verwendung von Fumarsäurederivaten zur Therapie der Herzinsuffizienz, der Hyperkeratose und von Asthma
DE14172396T1 (de) * 2004-10-08 2015-01-08 Forward Pharma A/S Gesteuerte Freisetzung von pharmazeutischen Zusammensetzungen mit Fumarinsäureester
CN101056624A (zh) * 2004-10-08 2007-10-17 Adi技术制药股份公司 包含富马酸酯的控释药物组合物
US20080227847A1 (en) * 2005-07-07 2008-09-18 Aditech Pharma Ab Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use
EP1951206A1 (en) * 2005-10-07 2008-08-06 Aditech Pharma AB Controlled release pharmaceutical compositions comprising a fumaric acid ester
WO2007042035A2 (en) * 2005-10-07 2007-04-19 Aditech Pharma Ab Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
WO2007079082A2 (en) * 2005-12-30 2007-07-12 Advancis Pharmaceutical Corporation Gastric release pulse system for drug delivery
US20090018175A1 (en) * 2007-04-25 2009-01-15 Itamar Kanari Pharmaceutical excipient complex
EP2227226B1 (en) * 2007-12-21 2016-10-26 Johnson & Johnson Consumer Inc. Manufacture of a tablet
RU2010151944A (ru) * 2008-05-20 2012-06-27 Серенис Терапьютикс С.А. (Fr) Ниацин и нспвс для комбинированной терапии
RU2554347C2 (ru) * 2008-08-19 2015-06-27 Ксенопорт, Инк. Пролекарства метилгидрофумарата, фармацевтические композиции с ними и способы применения
CN102369000A (zh) * 2009-01-09 2012-03-07 前进制药公司 包含一种或多种富马酸酯的药用组合物
CN109044985A (zh) 2009-01-09 2018-12-21 前进制药知识产权有限公司 包含溶蚀骨架中的一种或多种富马酸酯的药物制剂
NZ617130A (en) 2009-04-29 2015-06-26 Biogen Ma Inc Treatment of neurodegeneration and neuroinflammation
US20100285164A1 (en) 2009-05-11 2010-11-11 Jrs Pharma Orally Disintegrating Excipient
ME02317B (me) 2010-02-12 2016-06-20 Biogen Ma Inc Neuroprotekcija kod demijelinizacijskih bolesti
AU2013203445C1 (en) * 2012-02-07 2017-04-20 Biogen Ma Inc. Pharmaceutical compositions containing dimethyl fumarate

Similar Documents

Publication Publication Date Title
JP2017222705A5 (enExample)
JP2015506377A5 (enExample)
US10258622B2 (en) Method of treating colorectal cancer by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)pheny1)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl) carbamate
US20080014271A1 (en) Novel pharmaceutical compositions comprising levetiracetam
JP2022016638A (ja) イルベサルタンとアムロジピンまたはその塩を含有する医薬組成物
US20150209291A1 (en) High drug load tablet
US20200188380A1 (en) Pharmaceutical composition comprising lenvatinib mesylate
JP2020500176A (ja) 医薬製剤
CN102300558A (zh) 有机化合物的盖伦制剂
WO2009066315A2 (en) Sustained release compositions of trimetazidine and process for preparation thereof
KR101907116B1 (ko) 에스오메프라졸, 또는 약학적으로 허용 가능한 그의 염을 포함하는, pH-의존성 약물 방출 특성이 개선된 제형
JP2015501808A5 (enExample)
KR101907881B1 (ko) 로자탄, 암로디핀 및 히드로클로로티아자이드를 포함하는 고정 용량 조합 제형
US8895065B2 (en) Single unit oral dose pharmaceutical composition comprising levodopa, carbidopa and entacapone or salts thereof
AU2016231883B2 (en) Pharmaceutical compositions of dimethyl fumarate
US20190091204A1 (en) Compositions of deferasirox
WO2010023690A2 (en) Prolonged release formulation of amisulpride
KR20160076928A (ko) 푸마르산 에스테르를 함유하는 미니-정제 형태의 약제학적 제제
AU2013366640A1 (en) Tablet composition comprising cinacalcet hydrochloride
JP2019532960A (ja) エソメプラゾール含有複合カプセル剤及びその製造方法
WO2017145036A1 (en) Pharmaceutical compositions comprising dimethyl fumarate
WO2009087690A2 (en) Multiparticulate extended release pharmaceutical composition of carbamazepine and process for manufacturing the same
JP2015503555A (ja) ボセンタン制御放出性経口製剤
GR1010345B (el) Δισκια παρατεταμενης αποδεσμευσης που περιλαμβανουν ρανολαζινη και μεθοδος παραγωγης αυτων
WO2012050539A1 (en) Pharmaceutical composition comprising eplerenone